

# Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

## Search Orphan Drug Designations and Approvals

RRID:SCR\_010256

Type: Tool

---

### Proper Citation

Search Orphan Drug Designations and Approvals (RRID:SCR\_010256)

---

### Resource Information

**URL:** <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm>

**Proper Citation:** Search Orphan Drug Designations and Approvals (RRID:SCR\_010256)

**Description:** Database of Orphan Drug Product designations. Searches may be run by entering the product name, orphan designation, and dates. Results can be displayed as a condensed list, detailed list, or an Excel spreadsheet.

**Resource Type:** database, data or information resource

**Resource Name:** Search Orphan Drug Designations and Approvals

**Resource ID:** SCR\_010256

**Alternate IDs:** nlx\_156908

**Record Creation Time:** 20220129T080257+0000

**Record Last Update:** 20260808T190425+0000

---

### Ratings and Alerts

No rating or validation information has been found for Search Orphan Drug Designations and Approvals.

No alerts have been found for Search Orphan Drug Designations and Approvals.

---

### Data and Source Information

**Source:** [SciCrunch Registry](#)

---

### Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Mo Q, et al. (2025) Drug lag and associated factors of orphan drugs approved by the U.S. in China. *Frontiers in pharmacology*, 16, 1595497.

Lee J, et al. (2023) COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. *Journal of pharmaceutical investigation*, 53(2), 191.

Mechler K, et al. (2020) Disease awareness or subtle product placement? Orphan diseases featured in the television series "House, M.D." - a cross-sectional analysis. *BMC medical ethics*, 21(1), 20.

Boccanegra B, et al. (2020) Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks. *Pharmacological research*, 158, 104917.

Jaros??awski S, et al. (2017) Quantifying the persisting orphan-drug shortage public health crisis in the United States. *Journal of market access & health policy*, 5(1), 1269473.

Gibson S, et al. (2015) Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada. *Journal of law and the biosciences*, 2(2), 263.